CNTA

Centessa Pharmaceuticals plc

14 filings tracked

healthcarebiotechnologySMALL ($300M-2B)

Signal Magnitude Chart

bullish

bearish

neutral

Signal Timeline

bullishMay 22

Major regulatory hurdle (HSR) cleared for acquisition by Eli Lilly.

acquisition

90%

bullishMay 22

Expiration of antitrust waiting period reduces deal failure risk.

regulatory action

70%

bullishMay 22

Major regulatory hurdle (HSR) cleared for acquisition by Eli Lilly.

acquisition

90%

bullishMay 22

Expiration of antitrust waiting period reduces deal failure risk.

regulatory action

70%

bullishMay 22

Major regulatory hurdle (HSR) cleared for acquisition by Eli Lilly.

acquisition

90%

bullishMay 22

Expiration of antitrust waiting period reduces deal failure risk.

regulatory action

70%

bullishMay 22

Major regulatory hurdle (HSR) cleared for acquisition by Eli Lilly.

acquisition

90%

bullishMay 22

Expiration of antitrust waiting period reduces deal failure risk.

regulatory action

70%

bullishMay 22

Major regulatory hurdle (HSR) cleared for acquisition by Eli Lilly.

acquisition

90%

bullishMay 22

Expiration of antitrust waiting period reduces deal failure risk.

regulatory action

70%

bullishMay 22

Major regulatory hurdle (HSR) cleared for acquisition by Eli Lilly.

acquisition

90%

bullishMay 22

Expiration of antitrust waiting period reduces deal failure risk.

regulatory action

70%

bullishMay 5

Definitive agreement for Eli Lilly to acquire Centessa for $38/share plus CVRs.

acquisition

90%

bearishMay 5

Quarterly net loss increased to $79.2 million compared to prior year.

earnings miss

70%

bearishMay 5

R&D expenses surged by 79% YoY to $59.9 million.

margin compression

60%

bullishMay 5

Definitive agreement for Eli Lilly to acquire Centessa for $38/share plus CVRs.

acquisition

90%

bearishMay 5

Quarterly net loss increased to $79.2 million compared to prior year.

earnings miss

70%

bearishMay 5

R&D expenses surged by 79% YoY to $59.9 million.

margin compression

60%

bullishMay 5

Definitive agreement for Eli Lilly to acquire Centessa for $38/share plus CVRs.

acquisition

90%

bearishMay 5

Quarterly net loss increased to $79.2 million compared to prior year.

earnings miss

70%

bearishMay 5

R&D expenses surged by 79% YoY to $59.9 million.

margin compression

60%

bullishMay 5

Definitive agreement for Eli Lilly to acquire Centessa for $38/share plus CVRs.

acquisition

90%

bearishMay 5

Quarterly net loss increased to $79.2 million compared to prior year.

earnings miss

70%

bearishMay 5

R&D expenses surged by 79% YoY to $59.9 million.

margin compression

60%

bullishMay 5

Definitive agreement for Eli Lilly to acquire Centessa for $38/share plus CVRs.

acquisition

90%

bearishMay 5

Quarterly net loss increased to $79.2 million compared to prior year.

earnings miss

70%

bearishMay 5

R&D expenses surged by 79% YoY to $59.9 million.

margin compression

60%

bullishMay 5

Definitive agreement for Eli Lilly to acquire Centessa for $38/share plus CVRs.

acquisition

90%

bearishMay 5

Quarterly net loss increased to $79.2 million compared to prior year.

earnings miss

70%

bearishMay 5

R&D expenses surged by 79% YoY to $59.9 million.

margin compression

60%

bullishMay 5

Definitive agreement for Eli Lilly to acquire Centessa for $38/share plus CVRs.

acquisition

90%

bearishMay 5

Quarterly net loss increased to $79.2 million compared to prior year.

earnings miss

70%

bearishMay 5

R&D expenses surged by 79% YoY to $59.9 million.

margin compression

60%

bullishMar 31

Agreement to be acquired by Eli Lilly for $38/share plus CVRs.

acquisition

90%

neutralMar 31

Secured $110M loan from Oxford Finance to refinance previous debt.

debt restructure

50%

bearishMar 31

Continued high R&D burn rate with no current product revenue.

margin compression

60%

Filing History

8-KMay 22, 2026

Centessa Pharmaceuticals has reached a critical juncture in its merger with Eli Lilly following the expiration of the HSR Act waiting period. While this removes a primary regulatory obstacle, the deal's completion still hinges on court approval and shareholder consent. The market is now shifting its focus from antitrust risk to execution risk, as investors weigh the certainty of a pharmaceutical giant's buyout against the remaining legal and procedural requirements of a court-sanctioned scheme of arrangement.

10-QMay 5, 2026

The Q1 2026 filing presents a stark contrast between a highly attractive corporate transaction and a struggling operational core. The Eli Lilly agreement fundamentally alters the investment thesis, shifting the focus from long-term clinical viability to the probability of a successful merger closing. While the cash position is strong, the company's reliance on this exit is evident in its escalating losses and the collateralized nature of its debt. Investors are essentially trading a speculative biotech play for a merger arbitrage opportunity. The key tension lies in the execution risk: the gap between the current date and the Q3 2026 closing window. While the structural protections of the deal are significant, the underlying financial instability and the rigorous requirements for UK court sanctioning introduce a layer of risk that complicates the 'guaranteed' nature of the payout.

10-KMar 31, 2026

The 10-K reveals a company at a critical inflection point, balancing high-conviction scientific breakthroughs against the harsh realities of biotech financing. The Eli Lilly acquisition provides a clear exit path and a valuation floor, but the contingent value rights mean that a significant portion of the upside remains tied to unpredictable FDA milestones. The tension between the 'fortress balance sheet' and the debt-collateralized reality defines the current investment risk. Ultimately, the filing underscores a transition from an R&D-heavy discovery shop to a strategic asset within a larger pharmaceutical portfolio. While the scientific data for cleminorexton is compelling, the bear case highlights the fragility of the company's independent existence should the merger fail. Investors are essentially betting on the successful execution of the Lilly deal and the subsequent achievement of CVR triggers.